ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 574,60
-0,76%
Dow Jones
40 211,72
0,53%
DAX
18 472,55
-0,69%
Brent Oil
83,605
-0,87%
Bitcoin
62 710,23
-3,30%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
06/03/201922h10GlobeNewswire Inc.Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
06/03/201900h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/03/201920h52Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/03/201914h20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/03/201914h05GlobeNewswire Inc.Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
01/03/201914h03GlobeNewswire Inc.Portola Pharmaceuticals Enters into $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Manage...NASDAQ:PTLAPortola Pharmaceuticals Inc
01/03/201913h38GlobeNewswire Inc.European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal...NASDAQ:PTLAPortola Pharmaceuticals Inc
19/02/201914h25GlobeNewswire Inc.Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Exp...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201923h26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201917h58Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201916h03Edgar (US Regulatory)Schedule 13gNASDAQ:PTLAPortola Pharmaceuticals Inc
07/02/201922h03GlobeNewswire Inc.Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in...NASDAQ:PTLAPortola Pharmaceuticals Inc
04/02/201923h33Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/02/201914h30GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019NASDAQ:PTLAPortola Pharmaceuticals Inc
30/01/201914h43GlobeNewswire Inc.Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation a...NASDAQ:PTLAPortola Pharmaceuticals Inc
28/01/201915h23GlobeNewswire Inc.Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial OfficerNASDAQ:PTLAPortola Pharmaceuticals Inc
31/12/201821h19GlobeNewswire Inc.U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 M...NASDAQ:PTLAPortola Pharmaceuticals Inc
18/12/201814h30GlobeNewswire Inc.Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019NASDAQ:PTLAPortola Pharmaceuticals Inc
11/12/201813h00GlobeNewswire Inc.CHMP Extends Review Period for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa)NASDAQ:PTLAPortola Pharmaceuticals Inc
04/12/201803h15GlobeNewswire Inc.Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Contin...NASDAQ:PTLAPortola Pharmaceuticals Inc
07/11/201822h46Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
07/11/201822h05GlobeNewswire Inc.Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
06/11/201822h30GlobeNewswire Inc.Portola Pharmaceuticals to Participate in Two Upcoming Investor ConferencesNASDAQ:PTLAPortola Pharmaceuticals Inc
01/11/201822h30GlobeNewswire Inc.Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/11/201821h03GlobeNewswire Inc.Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American S...NASDAQ:PTLAPortola Pharmaceuticals Inc
23/10/201814h30GlobeNewswire Inc.Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2...NASDAQ:PTLAPortola Pharmaceuticals Inc
09/10/201815h05GlobeNewswire Inc.Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growin...NASDAQ:PTLAPortola Pharmaceuticals Inc
25/09/201822h38GlobeNewswire Inc.Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of...NASDAQ:PTLAPortola Pharmaceuticals Inc
20/09/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Names Scott Garland President and Chief Executive OfficerNASDAQ:PTLAPortola Pharmaceuticals Inc
12/09/201800h06GlobeNewswire Inc.U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa ...NASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

NASDAQ
IMACW
IMAC
LSE
0ON3
Vascory
TG
A28V2L
Province of Alberta
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés